Cowan Chad 4

What Happened

• Chad Cowan, Chief Scientific Officer of Century Therapeutics (IPSC), reported a disposal on 2026-03-11 where 1,431 shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units. The reported per-share value was $2.73, for a total of approximately $3,907. This was a tax-withholding event (code F), not an open-market sale.

Key Details

• Transaction date and type: 2026-03-11 — shares withheld for tax withholding on RSU vesting (reporting code F).
• Price: $2.73 per share; total value reported $3,907 (approx).
• Shares owned after transaction: Not specified in the provided filing details; the report notes certain shares are held by the Cowan Investment Nominee Trust and the reporting person disclaims beneficial ownership except for any pecuniary interest (see footnote).
• Footnotes:
  • F1: Shares were withheld by the issuer to satisfy tax withholding on vesting of restricted stock units.
  • F2: Some shares are held by the Cowan Investment Nominee Trust; Cowan disclaims beneficial ownership except to extent of pecuniary interest.
• Filing timeliness: Report filed 2026-03-13 for a 2026-03-11 transaction (filed within the typical Section 16 reporting window).

Context

• This was a routine tax-withholding disposal associated with RSU vesting (commonly referred to as a "sell to cover" or shares withheld) and not an active sale in the market. Such transactions are administrative and do not necessarily indicate insider sentiment about the company.